| Name | Title | Contact Details |
|---|
Commerzbank AG is a prominent German financial institution founded in 1870 in Hamburg. It has grown to become one of Germanys leading commercial banks, significantly contributing to the countrys economic development. The bank is headquartered in Frankfurt am Main, with around 400 branches across Germany and international locations in cities like New York, Singapore, and London. Commerzbank offers a wide range of financial services for both private and corporate clients. For individuals and businesses, it provides payment solutions, securities trading, investment products, and financing options, including real estate and corporate loans. The bank is known for its free checking account offer. For corporate clients, Commerzbank delivers tailored banking products, capital structuring assistance, and support for international business activities, including foreign exchange services. Additionally, it offers green mortgage loans focused on energy efficiency. Commerzbank plays a vital role in financing German foreign trade, supporting a significant portion of the countrys international trade activities.
Hawkins is a formulator, manufacturer, blender, distributor, and sales agent for thousands of industrial chemicals and reagent grade laboratory chemicals sold to municipalities and businesses throughout the Central United States. Thousands of water treatment facilities, manufacturers, food and dairy producers, research labs and many other organizations depend on Hawkins for the chemical products they need. These products range from potassium carbonate to chlorine to FCC grade citrates and phosphates. Our Mission To exceed our customers expectations as a high-quality, service-oriented chemical supplier. We will adapt quickly to the changing chemical needs of customers with a keen focus on technical expertise, teamwork, safety, profitability, and responsible care of the environment and of our community.
Universal Sompo is a Joint venture of Indian Bank, Indian Overseas Bank, Karnataka Bank, Dabur Investments, and Sompo Japan Insurance Inc. The companys paid-up capital is Rs 368 Cr; Shareholders Net worth is over Rs. 1269 Cr ; Gross Written Premium Rs. 4169 Cr ; Assets Under Management (AUM) Rs. 4386 Cr; Solvency at 1.73 times. The company is headquartered in Mumbai and has 151 offices countrywide with representation through its digitally enabled employees. It has a strong distribution network of Agents, Point of salespersons, Bank Branches, Automobile Dealers, Brokers, Common Service Centres, and Digital Platforms. The company offers 234 IRDAI-approved products and 1494 Add-on covers, ranging from Motor, Accident & Health, Home for Individuals, Shopkeepers Package, Crop and other non-life packages for SMEs, Fire, Marine, Engineering, Employees Benefit, Project Insurance, Liability, and other special products for Corporates. Microinsurance covers the Rural segment. The company maintains its Claims settlement ratio at 98.87% and has robust technology architecture to serve its customers nationwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Giupedi Utilizes Generative AI for High Quality Legal Client Acquisition Giupedi has created a unique Platform for advertising and marketing in the Workers Compensation, Medical Malpractice, and Personal Injury litigation industry. Prospective clients are empowered to make decisions and attorney selections in a manner that utilizes Generative AI and Secure Information Sharing.